遗传

• 综述 •    

mRNA展示技术高通量筛选环肽药物的研究进展

王爽1,2,朱雪1,2,方晶1,2,薛岩1,2,黄志洪1,2,王柯1,2   

  1. 1. 南京医科大学药学院核药学系, 南京 211166

    2. 国家卫生健康委员会核医学重点实验室江苏省分子核医学重点实验室,江苏省原子医学研究所,无锡 214063

  • 收稿日期:2025-08-13 修回日期:2025-10-20 发布日期:2025-10-31
  • 基金资助:

    国家自然科学基金项目(编号:82573711, 22407052,江苏省自然科学基金(编号:BK20240300),江苏省卫委科研项目(编号:MQ2024007H2023150K2024007),无锡市科技发展基金(编号:K20241060),无锡市委卫健委重大专项(编号:Z202303)和无锡科学技术协会(编号:TJXD-2024-102)资助

Shuang Wang 1,2, Xue Zhu 1,2, Jing Fang1,2, Yan Xue 1,2, Zhihong Huang 1,2, Ke Wang1,2   

  1. 1. Department of Radio Pharmaceuticais, School of Pharmacy, Nanjing Medical University, Nanjing 211166

    2. Jiangsu Institute of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, NHC Key Laboratory of Nuclear Medicine, Wuxi 214063

  • Received:2025-08-13 Revised:2025-10-20 Online:2025-10-31
  • Supported by:
    [Supported by the National Natural Science Foundation of China (Nos82573711, 22407052), the Natural Science Foundation of Jiangsu Province (No. BK20240300), the Scientific Research Projects of Jiangsu Health Commission (Nos. MQ2024007, H2023150, K2024007), the Wuxi Science and Technology Development Fund (No. K20241060), the Major Project of Wuxi Health Commission (No. Z202303), and the Wuxi Association for Science and Technology (No.TJXD-2024-102) ] 

摘要:

环肽作为突破传统药物开发难以成药靶点的重要分子形式凭借其独特的构象约束特性,成功弥了小分子药物与生物制剂的治疗间隙。尽管早期环肽的发现依赖天然产物挖掘,但是展示技术的出现将库容量提升至1015,加速了全新环肽药物的研发。mRNA展示技术作为一种基因型(mRNA)与表型(蛋白质)融合的体外多肽/蛋白质筛选技术,可在一次实验中筛选数万亿蛋白质变体以实现所需功能。近年来,随着利用mRNA展示技术筛选出的多肽药物进入临床研发阶段,从头开始的肽药物发现领域逐渐走向成熟。本文对mRNA展示技术的原理、特点以及其在环肽药物研发过程中的应用展开综述,以期为推动基于mRNA展示技术的原创性环肽药物发现提供新的思路和策略借鉴。

关键词:

mRNA展示技术, 体外筛选, 环肽药物, 多肽文库

Abstract:

Cyclic peptides have emerged as a promising therapeutic modality for targeting classically deemed "undruggable" protein that defy conventional small-molecule intervention. Their rigid conformations improve binding affinity, selectivity and proteolytic stability, bridging the gap between low-molecular-weight drugs and large biologics. Early cyclic peptide discovery relied on natural product isolation. However, display technologies now enable the generation and screening of libraries containing up to 10¹⁵ unique sequences. Among these, mRNA display technology offers a uniquely powerful in vitro platform that covalently links genotype (mRNA) to phenotype (encoded peptide), facilitating the ultrahigh-throughput interrogation of trillions of variants in a single selection cycle. Recent clinical translation of de novo mRNA display-derived cyclic peptides signals the approach’s maturation. In this review, we systematically evaluate mRNA display technology by outlining its methodological framework and highlighting its unique advantages for engineering macrocyclic therapeutics. We critically examine its transformative potential as well as its inherent limitations in identifying bioactive cyclic peptides, with particular attention to library diversity and the precision of on-resin screening. Through this analysis, we aim to provide insightful perspectives and strategic recommendations to guide future efforts in exploiting mRNA display for the development of innovative cyclic peptide-based drugs.

Key words:

mRNA display technology,  , in vitro , screening, cyclic peptide drug, peptide library